614 related articles for article (PubMed ID: 31687095)
1. Recent Clinical Trials Shed New Light on the Cardiovascular Benefits of Omega-3 Fatty Acids.
Kris-Etherton PM; Richter CK; Bowen KJ; Skulas-Ray AC; Jackson KH; Petersen KS; Harris WS
Methodist Debakey Cardiovasc J; 2019; 15(3):171-178. PubMed ID: 31687095
[TBL] [Abstract][Full Text] [Related]
2. Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options.
Weintraub H
Atherosclerosis; 2013 Oct; 230(2):381-9. PubMed ID: 24075771
[TBL] [Abstract][Full Text] [Related]
3. Omega-3 fatty acids for cardioprotection.
Lee JH; O'Keefe JH; Lavie CJ; Marchioli R; Harris WS
Mayo Clin Proc; 2008 Mar; 83(3):324-32. PubMed ID: 18316000
[TBL] [Abstract][Full Text] [Related]
4. Lipid effects of switching from prescription EPA+DHA (omega-3-acid ethyl esters) to prescription EPA only (icosapent ethyl) in dyslipidemic patients.
Crandell JR; Tartaglia C; Tartaglia J
Postgrad Med; 2016 Nov; 128(8):859-864. PubMed ID: 27684412
[TBL] [Abstract][Full Text] [Related]
5. The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention.
Trivedi K; Le V; Nelson JR
Postgrad Med; 2021 Jan; 133(1):28-41. PubMed ID: 32762268
[TBL] [Abstract][Full Text] [Related]
6. Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid.
Mason RP; Libby P; Bhatt DL
Arterioscler Thromb Vasc Biol; 2020 May; 40(5):1135-1147. PubMed ID: 32212849
[TBL] [Abstract][Full Text] [Related]
7. Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association.
Skulas-Ray AC; Wilson PWF; Harris WS; Brinton EA; Kris-Etherton PM; Richter CK; Jacobson TA; Engler MB; Miller M; Robinson JG; Blum CB; Rodriguez-Leyva D; de Ferranti SD; Welty FK;
Circulation; 2019 Sep; 140(12):e673-e691. PubMed ID: 31422671
[TBL] [Abstract][Full Text] [Related]
8. Omega-3 fatty acid therapy for cardiovascular disease: justified or not?
Maki KC; Dicklin MR
Curr Opin Cardiol; 2020 Jul; 35(4):417-422. PubMed ID: 32412960
[TBL] [Abstract][Full Text] [Related]
9. Omega-3 fatty acids for the prevention of atherosclerotic cardiovascular disease.
Barry AR; Dixon DL
Pharmacotherapy; 2021 Dec; 41(12):1056-1065. PubMed ID: 34431129
[TBL] [Abstract][Full Text] [Related]
10. Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements.
Miller M; Tokgozoglu L; Parhofer KG; Handelsman Y; Leiter LA; Landmesser U; Brinton EA; Catapano AL
Expert Rev Cardiovasc Ther; 2022 Aug; 20(8):609-625. PubMed ID: 35876118
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Disease Risk Reduction in Mild-Moderate Hypertriglyceridemia: Integrating Prescription of Omega-3 with Standard Treatment.
Picard F; Steg PG
Curr Atheroscler Rep; 2021 Mar; 23(6):27. PubMed ID: 33788024
[TBL] [Abstract][Full Text] [Related]
12. TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
Handelsman Y; Shapiro MD
Endocr Pract; 2017 Jan; 23(1):100-112. PubMed ID: 27819772
[TBL] [Abstract][Full Text] [Related]
13. Eicosapentaenoic Acid Versus Docosahexaenoic Acid as Options for Vascular Risk Prevention: A Fish Story.
Singh S; Arora RR; Singh M; Khosla S
Am J Ther; 2016; 23(3):e905-10. PubMed ID: 25828517
[TBL] [Abstract][Full Text] [Related]
14. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.
Kedia AW; Lynch E
Postgrad Med; 2015; 127(8):869-73. PubMed ID: 26453247
[TBL] [Abstract][Full Text] [Related]
15. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk.
Orringer CE; Jacobson TA; Maki KC
J Clin Lipidol; 2019; 13(6):860-872. PubMed ID: 31787586
[TBL] [Abstract][Full Text] [Related]
16. Icosapent ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol.
Bazarbashi N; Miller M
Expert Rev Cardiovasc Ther; 2020 Apr; 18(4):175-180. PubMed ID: 32228246
[TBL] [Abstract][Full Text] [Related]
17. Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues.
Sherratt SCR; Libby P; Budoff MJ; Bhatt DL; Mason RP
Curr Atheroscler Rep; 2023 Jan; 25(1):1-17. PubMed ID: 36580204
[TBL] [Abstract][Full Text] [Related]
18. Indications for omega-3 fatty acid supplementation in prevention of cardiovascular disease: From fish to pharmaceuticals.
Bosomworth NJ
Can Fam Physician; 2023 Jul; 69(7):459-468. PubMed ID: 37452000
[TBL] [Abstract][Full Text] [Related]
19. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial.
Nicholls SJ; Lincoff AM; Garcia M; Bash D; Ballantyne CM; Barter PJ; Davidson MH; Kastelein JJP; Koenig W; McGuire DK; Mozaffarian D; Ridker PM; Ray KK; Katona BG; Himmelmann A; Loss LE; Rensfeldt M; Lundström T; Agrawal R; Menon V; Wolski K; Nissen SE
JAMA; 2020 Dec; 324(22):2268-2280. PubMed ID: 33190147
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of hypertriglyceridemia with omega-3 fatty acids].
Miyoshi T; Ito H
Nihon Rinsho; 2013 Sep; 71(9):1650-4. PubMed ID: 24205729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]